Skip to main content
SpringerLink
Log in

Biologic Treatment of Crohn’s Disease: Briakinumab and Ustekinumab

  • Chapter
  • First Online:
Crohn's Disease and Ulcerative Colitis

  • 3032 Accesses

Abstract

Interleukin-12 and interleukin-23 are innate immune system inflammatory cytokines that drive interferon-gamma and interleukin-17 responses, respectively. IL-12 and IL-23 share the same protein subunit, p40, which is contained in each of their heterodimeric structures. Crohn’s disease is characterized by increased production of the IL-12/INFγ and IL-23/IL-17 cytokines. Targeting p40 in several animal models of Crohn’s disease such as TNBS and CD4CD45RBhigh T cell transfer colitis has resulted in successful prevention and treatment of established gut inflammation. Briakinumab and ustekinumab are fully human monoclonal antibodies being tested for treatment in human Crohn’s disease. Preliminary results of clinical trials suggest that the early success of this novel strategy may be improved with better understanding of the drug’s pharmacology in Crohn’s patients and the validation of biomarkers that identify high probability of clinical response and remission.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 249.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348–57.

    PubMed  CAS  Google Scholar 

  2. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157(3):1261–70.

    PubMed  CAS  Google Scholar 

  3. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112(4):1169–78.

    Article  PubMed  CAS  Google Scholar 

  4. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182(5):1281–90.

    Article  PubMed  CAS  Google Scholar 

  5. Simpson SJ, Shah S, Comiskey M, et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med. 1998;187(8):1225–34.

    Article  PubMed  CAS  Google Scholar 

  6. Wirtz S, Finotto S, Kanzler S, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol. 1999;162(4):1884–8.

    PubMed  CAS  Google Scholar 

  7. Liu Z, Geboes K, Heremans H, et al. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur J Immunol. 2001;31(5):1550–60.

    Article  PubMed  CAS  Google Scholar 

  8. Billiau A, Heremans H, Vandekerckhove F, et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol. 1988;140(5):1506–10.

    PubMed  CAS  Google Scholar 

  9. Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol. 1996;156(1):5–7.

    PubMed  CAS  Google Scholar 

  10. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179–89.

    Article  PubMed  CAS  Google Scholar 

  11. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314–24.

    Article  PubMed  CAS  Google Scholar 

  12. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310–6.

    Article  PubMed  CAS  Google Scholar 

  13. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25(2):309–18.

    Article  PubMed  CAS  Google Scholar 

  14. Ahern PP, Schiering C, Buonocore S, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity. 2010;33(2):279–88.

    Article  PubMed  CAS  Google Scholar 

  15. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1(7):553–62.

    Article  PubMed  CAS  Google Scholar 

  16. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med. 2002;195(9):1129–43.

    Article  PubMed  CAS  Google Scholar 

  17. Becker C, Dornhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006;177(5):2760–4.

    PubMed  CAS  Google Scholar 

  18. O’Connor Jr W, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603–9.

    Article  PubMed  Google Scholar 

  19. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70.

    Article  PubMed  CAS  Google Scholar 

  20. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12(1):9–15.

    Article  PubMed  Google Scholar 

  21. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–79.

    Article  PubMed  CAS  Google Scholar 

  22. Pannacione R, Sandborn W, Gordon G, et al. Briakinumab (anti-interleukin 12/23p40, ABT874) for treatment of Crohn’s disease. Am J Gastroenterol. 2010;105:S457.

    Google Scholar 

  23. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–7.

    Article  PubMed  CAS  Google Scholar 

  24. Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011;17(2):181–91.

    Article  PubMed  CAS  Google Scholar 

  25. Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402(5):797–812.

    Article  PubMed  CAS  Google Scholar 

  26. Cingoz O. Ustekinumab. MAbs. 2009;1(3):216–21.

    Article  PubMed  Google Scholar 

  27. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–41.

    Article  PubMed  CAS  Google Scholar 

  28. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease. Am J Gastroenterol. 2009;104(11):2768–73.

    Article  PubMed  CAS  Google Scholar 

  29. Ling P, Gately MK, Gubler U, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995;154(1):116–27.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, 1825 University Blvd., SHEL613, Birmingham, AL, 35294, USA

    Peter Mannon MD, MPH

Authors
  1. Peter Mannon MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Mannon MD, MPH .

Editor information

Editors and Affiliations

  1. Medical School of the Humboldt Universit, Department of Medicine, Charité Medical Center, Virchow Hospita, Berlin, 13344, Germany

    Daniel C. Baumgart

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Mannon, P. (2012). Biologic Treatment of Crohn’s Disease: Briakinumab and Ustekinumab. In: Baumgart, D. (eds) Crohn's Disease and Ulcerative Colitis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0998-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0998-4_34

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0997-7

  • Online ISBN: 978-1-4614-0998-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation